- Company
- Remsima SC is the idea of CEO Jung-jin Seo
- by An, Kyung-Jin Feb 19, 2020 06:35am
- [Vienna, Austria=Reporter An, Kyung-Jin] On the 15th (local time), the annual meeting of the European Crohn's Disease Colitis Association (ECCO 2020) completed a four-day campaign. The ECCO 2020 Conference, which marks the 15th anniversary of this year, was a place to realize that K-Bio's technology has taken a step up. The launch of t
- Company
- New migraine preventive Emgality cleared in general hospital
- by Eo, Yun-Ho Feb 19, 2020 06:34am
- Korean general hospitals are swiftly implementing a new migraine preventive medication, Emgality, on their prescription drug code. According to a pharmaceutical industry insider, migraine-preventing calcitonin gene-related peptide (CGRP) antagonist Emgality (galcanezumab) has been launched last December. And it has been passed by Drug C
- Company
- JW Holdings patent pancreatic cancer diagnostic kit in US
- by Nho, Byung Chul Feb 19, 2020 06:33am
- JW Holdings has also successfully patented an early-stage pancreatic cancer diagnostic technology in the U.S. JW Holdings (CEO Han Seong Gwon) announced on Feb. 17, the United States Patent and Trademark Office (USPTO) has granted a patent on source technology of the world’s first ‘multi-biomarker diagnostic kit’ that identifies pancr
- Company
- GSK and Pfizer intensify treatment conflicts after merger
- by An, Kyung-Jin Feb 18, 2020 06:34am
- There is a friction over the integration process of Pfizer Korea and GlaxoSmithKline's Consumer Health Division. Pfizer Pharmaceutical's union raises suspicions that GSK will endorse unfair changes in working conditions in the process of employee succession. There are ten days left to launch an integrated corporation, and a possibility that v
- Company
- Belviq was withdrawn voluntarily by Ildong
- by Chon, Seung-Hyun Feb 18, 2020 06:34am
- Ildong Pharmaceuticals voluntarily discontinued the sale of its obesity drug, Belviq. In the United States, it was advised to withdrawal of permission because of the risk of developing cancer, and it has preemptively discontinued sales in Korea. According to the industry on the 14th, Ildong Pharmaceutical decided to stop selling Belviq in Kor
- Company
- Delstrigo by MSD was approved
- by Eo, Yun-Ho Feb 14, 2020 06:36am
- MSD aims to expand market share in AIDS According to the industry, the MFDS recently approved a fixed-dose HIV complex, Delstrigo (Doravirine, Lamivudine, Tenofovir), once daily. Delstrigo has been approved for the treatment of human immunodeficiency virus (HIV-1) infections in adults without prior antiretroviral treatment. Doravirin
- Company
- Celebrex, resupplied as bottles of 100 capsules
- by Jung, Hye-Jin Feb 14, 2020 06:35am
- Cerebrex capsules, which are widely prescribed for rheumatoid and osteoarthritis pain medications, run out of stock. Pfizer Upjohn Korea recently announced that Celebrex 100mg 30 unit doses were sold out to distributors and medical institutions. Pfizer Korea explained that it will be resupplyed in early April and that Celebrex 100mg bot
- Company
- 4th IL inhibitor Skyrizi takes steps towards reimbursement
- by Eo, Yun-Ho Feb 13, 2020 06:29am
- The fourth interleukin medicine in Korean market, Skyrizi has started its reimbursement listing procedure. Pharmaceutical industry sources reported AbbVie Korea recently submitted an application for reimbursement on interleukin-23 (IL-23) inhibitor Skyrizi prefilled syringe (risankizumab). As a follow-on drug, the medication is predi
- Company
- Who will distribute Lamisil?
- by Jung, Hye-Jin Feb 13, 2020 06:28am
- GlaxoSmithKline Consumer Health's 'Lamisil' distribution network is distant. All rights reserved by Dong-wha have been transferred to Ildong. Only Lamisil has been missing and haven't found a supplier for over a month. Wholesalers and medical institutions are holding back their existing inventory and are very nervous about their short expi
- Company
- Yuhan and Eisai ink co-marketing deal for PPI Pariet
- by Eo, Yun-Ho Feb 12, 2020 06:31am
- Yuhan is to join the effort to market PPI medication Pariet in Korea. According to pharmaceutical industry sources, Pariet supplier Eisai Korea and Yuhan have signed a co-marketing contract on marketing and sales in Korea for proton pump inhibitor (PPI) medication Pariet (rabeprazole sodium) 5 mg as it has been listed for reimbursement s
